Scarica l'app Stockscreener
5.43
6.26%
0.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$5.11
Aprire:
$5.13
Volume 24 ore:
1.39M
Relative Volume:
1.06
Capitalizzazione di mercato:
$749.25M
Reddito:
$62.04M
Utile/perdita netta:
$-533.34M
Rapporto P/E:
-1.3852
EPS:
-3.92
Flusso di cassa netto:
$-473.07M
1 W Prestazione:
+4.62%
1M Prestazione:
+7.10%
6M Prestazione:
-25.31%
1 anno Prestazione:
-38.64%
Intervallo 1D:
$5.015
$5.44
Intervallo di 1 settimana:
$4.91
$5.44
Portata 52W:
$4.32
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Confronta VIR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.43 | 749.25M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com
Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener
(VIR) Trading Advice - news.stocktradersdaily.com
Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia
Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com Nigeria
Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace
Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus
Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace
Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus
Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia
Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus
How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com
How To Trade (VIR) - news.stocktradersdaily.com
Vir announces 24-week post-end of treatment data for Hep B therapy - MSN
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN
Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Vir Biotechnology Announces Results of Its Potential Hepatitis B Cure Combination Therapy - ContagionLive
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance
Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Trea - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Tr - GuruFocus
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus
Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):